MelAASarc: Melatonin Plus Aminoacids for Sarcopenic Elderly

Sponsor
Azienda di Servizi alla Persona di Pavia (Other)
Overall Status
Completed
CT.gov ID
NCT03784495
Collaborator
(none)
159
1
4
17
9.4

Study Details

Study Description

Brief Summary

To evaluate the effectiveness of melatonin and essential aminoacid supplementation on body composition, protein metabolism, strength and inflammation. The investigators performed a Randomized controlled parallel groups preliminary trial in 159 elderly sarcopenic people (42/117 men/women) assigned to 4 groups: isocaloric placebo (P, n=44), melatonin (M, 1 mg/daily, n=42,), essential aminoacids (eAA 4 g/daily, n=40) or eAA plus melatonin (eAAM, 4 g eAA and 1 mg melatonin/daily, n= 30). The period of intervention was 4 weeks. Data from body composition (DXA), strength (handgrip test) and biochemical parameters for the assessment of protein metabolism (albumin) and inflammation (PRC) were collected at baseline and after the 4-week intervention

Condition or Disease Intervention/Treatment Phase
  • Drug: Melatonin 1mg
  • Dietary Supplement: Essential Aminoacids (eAA)
  • Combination Product: Essential Aminoacids + melatonin
  • Other: Placebo
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
159 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Is a Combination of Melatonin and Aminoacids Useful to Sarcopenic Elderly Patients? A Randomized Trial
Actual Study Start Date :
Jan 1, 2014
Actual Primary Completion Date :
Dec 31, 2014
Actual Study Completion Date :
Jun 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo (P)

Placebo.

Other: Placebo
an isocaloric amount of maltodextrin with the same flavor and appearance as the intervention product

Experimental: Melatonin (M)

1 mg/day of melatonin.

Drug: Melatonin 1mg
1 mg/day 30 minutes before sleep

Experimental: Essential Aminoacids (eAA)

4 g/day of essential aminoacids

Dietary Supplement: Essential Aminoacids (eAA)
4g/day of Essential Aminoacids during breakfast. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.

Experimental: Essential Aminoacids + Melatonin (eAAM)

4 g/day of essential aminoacids and 1 mg/day of melatonin

Combination Product: Essential Aminoacids + melatonin
4g/day of Essential Aminoacids during breakfast + 1 mg/day of Melatonin 30 minutes before sleep. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.

Outcome Measures

Primary Outcome Measures

  1. Change in Total Fat Mass and Total Free Fat Mass (DXA) [0, 30 days]

    Body composition by dual-energy X-ray absorptiometry (DXA). Body composition was measured by DXA, using a Lunar Prodigy DXA (GE Medical Systems, Waukesha, WI). Free Fat mass and Fat mass of specific body regions were measured in kilograms.

  2. Change in Handgrip Strenght [0, 30 days]

    Handgrip strength assessed using a Jamar dynamometer adhering to the standardized protocol recommended by the American Society of Hand Therapists. A weak handgrip was defined as <30 kg for men and <20 kg for women, based on the average value of the two handgrip measurements of the dominant hand

Secondary Outcome Measures

  1. Height [At baseline (0)]

    Height measured in meters

  2. Change in Body Weight [0, 30 days]

    Body Weight measured in kilograms

  3. Change in serum proteins [0, 30 days]

    Serum proteins and albumin were measured by automatic biochemical analyzer. They were reported as g/dl

  4. Change in blood lipids (total cholesterol and triglycerides) [0, 30 days]

    Blood lipids (total cholesterol and triglycerides)were measured by automatic biochemical analyzer. They were reported as mg/dl

  5. Change in High-sensitivity C-reactive protein (CRP) [0, 30 days]

    High-sensitivity C-reactive protein (CRP) was expressed in mg/dl.

  6. Change in erythrocyte sedimentation rate (ESR) [0, 30 days]

    Erythrocyte sedimentation rate (ESR) was expressed in mm/hr.

  7. Change in glycaemia [0, 30 days]

    glycemia was expressed in mg/dl

  8. Change in Mini Nutritional Assessment (MNA) [0, 30 days]

    A mini nutritional assessment (MNA) was performed for all participants. The MNA uses 18 questions regarding simple measurements and a brief questionnaire involving an anthropometric assessment (weight, height and weight loss), a general assessment (lifestyle, medication and mobility), and a dietary assessment (number of meals, food and fluid intake, self-assessment of eating autonomy and self-perception of health and nutrition). Every answer give up to a maximum of 3 points. The sum of all points gives the total MNA. A maximum of 30 points can be achieved. A score of ≥ 24 points describes a well-nourished status. A score of 17 to 23.5 points indicates a risk of malnutrition, while less than 17 points indicates malnutrition.

  9. Change in dietary intake [Measures taken at day 1,2,3 and at day 28,29,30]

    A trained dietitian used a calibrated dietetic spring scale to weigh all foods served and returned for 3 consecutive days at the beginning and end of the study

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged > or equal 65 years

  • Sarcopenic patients, following the Rosetta Study criteria: Skeletal Muscle Index [SMI] was <7.23 kg/m2 in men and <5.45 kg/m2 in women) and loss of strength, evaluated by dynamometer and defined as <30 kg for men and <20 kg for women, using the average value of the two handgrip measurements of the dominant hand.

Exclusion Criteria:
  • acute illnesses

  • severe liver dysfunction

  • severe heart dysfunction

  • severe kidney dysfunction

  • severe dementia

  • uncontrolled diabetes

  • dysthyroidism

  • any endocrinopathies

  • neoplasia

  • patients treated with steroids

  • patients entirely unable to walk

Contacts and Locations

Locations

Site City State Country Postal Code
1 Geriatric physical medicine and rehabilitation division at the Istituto Santa Margherita - Azienda di Servizi alla Persona di Pavia Pavia Italy 27100

Sponsors and Collaborators

  • Azienda di Servizi alla Persona di Pavia

Investigators

  • Study Director: Mariangela Rondanelli, Professor, IRCCS Mondino Foundation, Pavia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mariangela Rondanelli, MD, Associate Professor, Azienda di Servizi alla Persona di Pavia
ClinicalTrials.gov Identifier:
NCT03784495
Other Study ID Numbers:
  • 1215/11122015
First Posted:
Dec 24, 2018
Last Update Posted:
Dec 24, 2018
Last Verified:
Dec 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 24, 2018